These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27390104)

  • 1. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
    Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
    Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.
    Katz JS; Frankel H; Ma T; Zagzag D; Liechty B; Zeev BB; Tzadok M; Devinsky O; Weiner HL; Roth J
    Childs Nerv Syst; 2017 Apr; 33(4):601-607. PubMed ID: 28074282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex.
    Boer K; Troost D; Timmermans W; Gorter JA; Spliet WG; Nellist M; Jansen F; Aronica E
    Neuroscience; 2008 Sep; 156(1):203-15. PubMed ID: 18706978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.
    Buccoliero AM; Franchi A; Castiglione F; Gheri CF; Mussa F; Giordano F; Genitori L; Taddei GL
    Neuropathology; 2009 Feb; 29(1):25-30. PubMed ID: 18564101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
    Cheng S; Hawkins C; Taylor MD; Bartels U
    Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR pathway activation in focal cortical dysplasia.
    Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M
    Ann Diagn Pathol; 2020 Jun; 46():151523. PubMed ID: 32325422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
    Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
    Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
    Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
    Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
    Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
    Tyburczy ME; Kotulska K; Pokarowski P; Mieczkowski J; Kucharska J; Grajkowska W; Roszkowski M; Jozwiak S; Kaminska B
    Am J Pathol; 2010 Apr; 176(4):1878-90. PubMed ID: 20133820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis.
    Miyata H; Chiang AC; Vinters HV
    Ann Neurol; 2004 Oct; 56(4):510-9. PubMed ID: 15455398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study.
    Hirose T; Scheithauer BW; Lopes MB; Gerber HA; Altermatt HJ; Hukee MJ; VandenBerg SR; Charlesworth JC
    Acta Neuropathol; 1995; 90(4):387-99. PubMed ID: 8546029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma.
    Barrows BD; Rutkowski MJ; Gültekın SH; Parsa AT; Tıhan T
    Turk Patoloji Derg; 2012; 28(2):95-103. PubMed ID: 22627626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases.
    Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M; Gupta RK; Saran RK
    Neurol India; 2016; 64(5):988-94. PubMed ID: 27625244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D; Franz DN
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
    Jóźwiak S; Nabbout R; Curatolo P;
    Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of microRNAs miR21, miR146a, and miR155 in tuberous sclerosis complex cortical tubers and their regulation in human astrocytes and SEGA-derived cell cultures.
    van Scheppingen J; Iyer AM; Prabowo AS; Mühlebner A; Anink JJ; Scholl T; Feucht M; Jansen FE; Spliet WG; Krsek P; Zamecnik J; Buccoliero AM; Giordano F; Genitori L; Kotulska K; Jozwiak S; Jaworski J; Liszewska E; van Vliet EA; Aronica E
    Glia; 2016 Jun; 64(6):1066-82. PubMed ID: 27014996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex.
    Tsai JD; Wei CC; Tsao TF; Hsiao YP; Tsai HJ; Yang SH; Tsai ML; Sheu JN
    Childs Nerv Syst; 2016 Jan; 32(1):89-95. PubMed ID: 26552385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.